Pear Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pear Therapeutics, Inc.
The pandemic has led to a rise in sleep problems. Somryst seeks to address chronic insomnia by training the body and brain to fall asleep faster and stay asleep longer.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
Will FDA-cleared prescription digital therapeutics be able to follow wellness, chronic disease and sleep disorder apps onto the formularies of major payers? For digital therapeutics companies investing in randomized controlled clinical trials, GMP manufacturing and FDA submissions for products, the current absence of public health insurance coverage is frustrating.
- Digital Health
- Medical Devices